# Table of Contents

**Introduction** .......................................................................................................................... 5

**Diagnosis** .................................................................................................................................... 8
  - Determining the Diagnosis ........................................................................................................... 8
  - Laboratory Tests .......................................................................................................................... 11
  - Patient Assessment ...................................................................................................................... 11
  - Imaging ......................................................................................................................................... 12

**Treatment** .................................................................................................................................... 13
  - Pharmacologic Therapy Overview .............................................................................................. 15
  - Initial Treatment of DMARD-naïve Patients ................................................................................. 17
    - Methotrexate (MTX) .................................................................................................................. 18
    - Patients with an Adequate Response to Methotrexate (MTX) at 3 Months ..................... 22
    - Patients with an Inadequate Response to Methotrexate (MTX) at 3 Months .............. 22
    - Methotrexate Polyglutamate (MTX PG) Levels ...................................................................... 23
    - Patients Receiving Subcutaneous Methotrexate (SQ MTX) Initially .................................. 32
    - Patients with a Contraindication to Methotrexate (MTX) .................................................... 32
    - Treatment with boDMARDs, bsDMARDs, or a tsDMARD .................................................... 32

**Monitoring** .................................................................................................................................. 36
  - Depression ..................................................................................................................................... 37
  - Patient Reported Outcomes (PRO) ............................................................................................. 38

**Glossary** ...................................................................................................................................... 39

**Appendix** .................................................................................................................................... 40
  - CDAI Calculator .......................................................................................................................... 40

**References** .................................................................................................................................... 41

**Document Updates** .................................................................................................................... 47
List of Tables

Table 1. Extra-articular manifestations of RA ........................................................................................................... 6
Table 2. Point allocation for the classification of RA according to the ACR/EULAR criteria ....................... 10
Table 3. Disease activity categories according to the CDAI scoring system ................................................. 14
Table 4. Drugs used in the management of RA.................................................................................................... 16

List of Figures

Figure 1. Initial pharmacologic management of DMARD-naïve patients with RA and no contraindication to MTX.............................................................................................................. 20
Figure 2. Initial pharmacologic management of DMARD-naïve patients with RA and a contraindication to MTX.......................................................................................................................... 21
Figure 3. Pharmacologic management of patients with RA and therapeutic levels of MTX PG and either <50% improvement in CDAI after 3 months of treatment with MTX or failure to attain remission after 6 months of MTX..................................................................... 25
Figure 4. Pharmacologic management of patient with RA and subtherapeutic levels MTX PG who have had either <50% improvement in CDAI after 3 months of treatment with oral MTX or failure to attain remission after 5 months of oral MTX................................................. 26
Figure 5. Pharmacologic management of patients with RA and no MTX PG levels with either <50% improvement in CDAI after 3 months of treatment with oral MTX or failure to attain remission after 5-6 months treatment with oral MTX. ........................................................................... 31
Figure 6. Pharmacologic management of patients with RA who failed oral or parenteral MTX, leflunomide or hydroxychloroquine, or sulfasalazine but had an adequate response to either a boDMARD, bsDMARD, or a tsDMARD................................................................................... 34
Figure 7. Pharmacologic management of patients with RA who failed conventional DMARDs and did not have an adequate response to combination DMARDs or a biologic ................. 35
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACPA</td>
<td>Anti-citrullinated protein antibody. Also: anti CCP</td>
</tr>
<tr>
<td>ACR</td>
<td>American College of Rheumatology</td>
</tr>
<tr>
<td>boDMARDs</td>
<td>Originator biologic disease-modifying antirheumatic drugs</td>
</tr>
<tr>
<td>bsDMARDs</td>
<td>Biosimilar disease-modifying antirheumatic drugs</td>
</tr>
<tr>
<td>CBC</td>
<td>Complete blood count</td>
</tr>
<tr>
<td>CDAI</td>
<td>Clinical Disease Activity Index</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>csDMARDs</td>
<td>Conventional synthetic disease-modifying antirheumatic drugs</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>DAS28</td>
<td>Disease activity score, based on 28 joints</td>
</tr>
<tr>
<td>DMARDs</td>
<td>Disease-modifying antirheumatic drugs</td>
</tr>
<tr>
<td>DMPA</td>
<td>Depot medroxyprogesterone acetate</td>
</tr>
<tr>
<td>EHRs</td>
<td>Electronic health records</td>
</tr>
<tr>
<td>ESR</td>
<td>Erythrocyte sedimentation rate</td>
</tr>
<tr>
<td>EULAR</td>
<td>European League Against Rheumatism</td>
</tr>
<tr>
<td>HBV</td>
<td>Hepatitis B virus</td>
</tr>
<tr>
<td>HDA</td>
<td>High disease activity</td>
</tr>
<tr>
<td>HLA-DRB1</td>
<td>Human leukocyte antigen D related beta 1</td>
</tr>
<tr>
<td>IL-6</td>
<td>Interleukin 6</td>
</tr>
<tr>
<td>IU</td>
<td>International units</td>
</tr>
<tr>
<td>IUDs</td>
<td>Intrauterine devices</td>
</tr>
<tr>
<td>LDA</td>
<td>Low disease activity</td>
</tr>
<tr>
<td>MDA</td>
<td>Moderate disease activity</td>
</tr>
<tr>
<td>MDHAQ</td>
<td>Multidimensional Health Assessment Questionnaire</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>MTX</td>
<td>Methotrexate</td>
</tr>
<tr>
<td>MTX PG</td>
<td>Methotrexate polyglutamate</td>
</tr>
<tr>
<td>PG</td>
<td>Polyglutamate</td>
</tr>
<tr>
<td>PGA</td>
<td>Physician Global Assessment</td>
</tr>
<tr>
<td>PRO</td>
<td>Patient reported outcomes</td>
</tr>
<tr>
<td>PtGA</td>
<td>Patient Global Assessment</td>
</tr>
<tr>
<td>PTPN22</td>
<td>Protein tyrosine phosphatase non-receptor type 22</td>
</tr>
<tr>
<td>QoL</td>
<td>Quality of life</td>
</tr>
<tr>
<td>RA</td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td>RAPID 3</td>
<td>Routine Assessment of Patient Index Data 3</td>
</tr>
<tr>
<td>RF</td>
<td>Rheumatoid factor</td>
</tr>
<tr>
<td>SQ MTX</td>
<td>Subcutaneous methotrexate</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
</tr>
<tr>
<td>tsDMARDs</td>
<td>Targeted synthetic disease-modifying antirheumatic drugs</td>
</tr>
<tr>
<td>ULN</td>
<td>Upper limit of normal</td>
</tr>
<tr>
<td>US</td>
<td>United States</td>
</tr>
<tr>
<td>VAS</td>
<td>Visual acuity scale</td>
</tr>
</tbody>
</table>
Introduction

Rheumatoid arthritis (RA) is a multisystem autoimmune disease affecting primarily diarthrodial joints of the hands and feet; however, it can also affect larger joints (shoulder, elbow, hip, ankle, and knee). The disease causes joint inflammation, synovial hyperplasia, and synovitis with increased synovial vascularity. Inflammatory cells within the joint lead to synovial proliferation and pannus formation, which ultimately results in the destruction of articular cartilage and bone.\(^1\)\(^2\) Rheumatoid arthritis is three times more common in women than in men,\(^3\) and can begin at any age. However, it is usually diagnosed between the ages of 18 and 60 years in women and over the age of 45 years in men.\(^4\) Although the odds of developing RA are increased in first-degree relatives of people who have the disease, most people with RA do not have a family history of it.\(^5\)

The destructive process in RA is thought to be related to an overproduction of a number of inflammatory cytokines, including tumor necrosis factor (TNF) and interleukin-6 (IL-6).\(^6\)\(^7\)

Some important factors possibly associated with an increased risk of RA include:\(^8\)\(^14\)

- Smoking
- Bacteria in the lungs
- Chronic periodontitis
- Silica exposure
- Air pollution
- Changes in gut flora

Studies of families with twins suggest that genetics contribute at least 50% to the etiology of RA.\(^15\) The presence of human leukocyte antigen D related Beta 1 (HLA-DRB1) or protein tyrosine phosphatase non-receptor type 22 (PTPN22) alleles are associated with an increased risk for RA. However, different genetic risks may be seen in different ethnic groups.\(^16\)\(^17\)

Rheumatoid arthritis is frequently but not always associated with the production of auto-antibodies such as rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA or anti-CCP).

A more recently described serum marker for RA is 14-3-3\(\eta\). According to Maksymowycz et al.,\(^18\) the use of this marker in addition to ACPA and RF may improve the identification of patients with early RA and, when elevated, 14-3-3\(\eta\) can be used as a prognostic indicator of more severe disease.

In addition to joint destruction, RA is characterized by serious extra-articular manifestations (Table 1), which tend to occur more frequently in patients with severe, active disease; in those who test positive for RF and ACPA; in men; and in patients with a history of smoking at the time of diagnosis. Extra-articular manifestations of RA include rheumatoid nodules, inflammatory eye disease, hematologic abnormalities, Felty’s syndrome, rheumatoid lung, and vasculitis. Extra-articular manifestations are associated with increased mortality.\(^15\)\(^20\)
Rheumatoid arthritis is incurable. The disease is characterized by intermittent exacerbations (also known as flares) and is often more active during the first few years after diagnosis. However, with proper management, patients can achieve periods of complete or near complete remission or stabilization of symptoms. Flares can occur, even in patients with previously good control. Flares or acute worsening of inflammation is manifested by increased joint pain and swelling, and systemic complaints such as fatigue and difficulty with activities of daily living. Patients should be evaluated as soon as possible during an acute flare, because additions or changes in medication are often needed to regain control.

Historically, RA (especially non-treated or inadequately treated disease) was associated with a decrease in life expectancy by, on average, 5 to 10 years. However, with the availability of better treatment, this is no longer the case. A study published in 2016 compared the death rates of patients diagnosed with RA between 1996 and 2000 with those diagnosed between 2001 and 2006 and found that the death rate in the first 5 years after diagnosis had decreased for those more recently diagnosed.21 The authors speculate that this may be due to improved management and better control of inflammation.
Patients with RA also have an increased risk for coronary heart disease, even before they are diagnosed with RA, and are more likely than patients without RA to have an unrecognized myocardial infarction or experience sudden death. They also have an increased risk of stroke, lung cancer, nonmelanoma skin cancer, and lymphoma when compared to the general population.\textsuperscript{22-24} Patients with RA have an increased risk for serious infections, including tuberculosis (TB), which may be related to the immunologic abnormalities associated with the disorder as well as the immunosuppressive effects of the drugs used to treat this disease.\textsuperscript{25}

Patients with RA report a diminished quality of life (QoL) compared to those without arthritis. According to Gabriel et al.,\textsuperscript{26} 15% of patients with RA reported that they were unable to find employment because of their disease, as opposed to only 3% of those with osteoarthritis and 1% of those without arthritis. Patients with RA are more likely to retire early or lose their jobs than the general population. Some patients decrease their work hours voluntarily because of limitations from their illness. In another study, 40% of patients with RA were more likely to report fair or poor general health when compared to nonarthritic controls. They also were 30% more likely to need help with activities of daily living and twice as likely to have some limitation of activity due to RA.\textsuperscript{27}

Rheumatoid arthritis care is very costly. In 2012, Kawatkar et al.\textsuperscript{28} compared the annual direct medical costs associated with caring for these patients with a control group of patients without RA, based on the 2008 Medical Expenditure Panel Survey. Overall, the annual cost of caring for RA patients was $22.3 billion dollars in 2008. Importantly, the cost of drugs was the greatest contributor to the overall cost of RA patients’ care, whereas prior to 2008, most studies reported that inpatient hospital stays were the greatest contributor to overall costs. Interestingly, Kawatkar et al.\textsuperscript{28} found that 26.6% of the RA patients had one comorbidity and 24.0% had two or more comorbidities whereas, in the non-RA group, 71.5% had no comorbidities, 22.1% had one, and only 6.5% had two or more comorbidities. Drug costs were nearly 40% of the total cost of care in the RA group but only 29% of the total in the non-RA group. In 2008, the total direct medical costs of caring for an RA patient averaged $13 012; those for a patient in the control group were $4950. The pharmacy expense was $5825 for an RA patient and $1264 for a patient in the control group.\textsuperscript{28}

However, when discussing financial burden, it is also important to consider the overall costs to employers, which include not only the cost of health insurance premiums but also the cost of disability insurance, absenteeism, reduced productivity, and early retirement. A systematic review of 38 papers concerning work disability, limitation, and absenteeism secondary to RA revealed that about two thirds of employed individuals with RA were absent from their jobs for a median duration of 39 days per year.\textsuperscript{29} A 2005 study of 6396 patients with RA in the United States (US) reported that patients had income losses between $2319 and $3407 per year.\textsuperscript{30} In addition, almost one third of those under the age of 65 years considered themselves disabled 15 years after diagnosis.

The continued increases in the cost of drugs escalate the cost of care. However, new medications introduced over the past two decades, have dramatically improved the lives of patients with RA. Although a cure has not yet been realized, these medications have been shown to slow or prevent the progression of the disease.

In 2012, Hallert et al.\textsuperscript{31} published a paper demonstrating a significant decrease in disability in patients with RA who took biologics. The dramatic impact of these drugs can be life changing for many patients. Improvement in QoL associated with the use of biologic agents has led to a decrease in cost of
disability, early retirement, work hours lost, and reduced productivity. In addition, recent studies have found that both joint replacement and soft-tissue surgical procedures have decreased, probably as a result of more effective treatments.32-34 One study evaluated RA patients in California over 40 years of age for trends in total knee replacement, total hip replacement, total ankle replacement or fusion, and total wrist replacement or fusion between 1983 and 2007.33 The rate of joint surgery was highest in the 1990s. The authors reported that, for patients between 40 and 59 years of age, the rate of knee surgery decreased by 19% between 2003 and 2007 when compared to knee surgery between 1983 and 1987; hip surgery decreased by 40% during the same time interval. However, for patients over the age of 60 years, there was no significant change.

The United Rheumatology Clinical Practice Guideline for RA is designed to assist healthcare professionals to diagnose, treat, and monitor patients with RA with the goal of preserving function, optimizing the number of patients who achieve remission or near remission, improving QoL, and monitoring outcomes in the safest and most cost-effective fashion possible.

Diagnosis

The workup of patients with suspected RA should be done by a rheumatologist and is based on clinical findings. Early in the course of the disease, symptoms may be subtle. There is no definitive laboratory test for the disorder, and X-rays may be normal. Patients usually present with complaints of joint pain, tenderness, swelling, and stiffness. Prolonged morning stiffness lasting ≥30 minutes is common. Symptoms are typically bilateral and symmetric but may be asymmetric, particularly at the onset of the disease. Small joints of the wrists, hands, and feet are commonly affected. In addition, systemic symptoms such as fatigue, low-grade fever, and weight loss may be reported.

Irreversible destructive joint changes may occur early in the course of the disease. Because current pharmacologic treatments can minimize joint destruction, it is important to establish the diagnosis of RA and begin appropriate treatment as early as possible, preferably before joint destruction occurs. The use of disease-modifying antirheumatic drugs (DMARDs), including biologic agents, has dramatically changed the long-term course of this disease.

Determining the Diagnosis

In 2010, the American College of Rheumatology (ACR), in collaboration with the European League Against Rheumatism (EULAR), published criteria for the classification of RA that were aimed at new patients.35 They were designed to classify patients for clinical trials. According to these classification criteria, any patient presenting with clinical evidence of synovitis in ≥1 joint for which there was no alternative diagnosis to explain the finding should be evaluated for RA. Classification criteria are based on four domains:

1. Number and site of joints involved (score range, 0 to 5)
2. Serological abnormalities (score range, 0 to 3)
3. Elevated acute-phase reactants (score range, 0 to 1)
   a. C-reactive protein (CRP) or
   b. Erythrocyte sedimentation rate (ESR)
4. Duration of symptoms (score range, 0 to 1)
Each of these domains is assigned a score. A total score of ≥6 is required to establish a classification of definite RA. A patient with a score of <6 does not definitively classified as having RA but may reach a score of ≥6 at a future visit and therefore may be at risk for the disorder. The point allocation is shown in Table 2.

Using the ACR/EULAR classification system, a patient may score 6 points and be classified as having RA without any positive laboratory tests (e.g., ≥10 joints involved [5 points] and duration of symptoms for ≥6 weeks [1 point]).
### Table 2. Point allocation for the classification of RA according to the ACR/EULAR criteria

<table>
<thead>
<tr>
<th>Symptoms and Joint Count</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>(any swollen or tendon joint; excluding any: distal interphalangeal joints; 1&lt;sup&gt;st&lt;/sup&gt; metacarpophalangeal joints; and 1&lt;sup&gt;st&lt;/sup&gt; metatarsophalangeal joints)</td>
<td></td>
</tr>
<tr>
<td>1 large joint (Shoulder, elbow, hip, knee, or ankle)</td>
<td>0</td>
</tr>
<tr>
<td>2 to 10 large joints (Shoulder, elbow, hip, knee, or ankle)</td>
<td>1</td>
</tr>
<tr>
<td>1 to 3 small joints (may also have large joints) (Wrist; metacarpophalangeal, proximal interphalangeal, or 2&lt;sup&gt;nd&lt;/sup&gt; – 5&lt;sup&gt;th&lt;/sup&gt; metatarsophalangeal joints; or interphalangeal joint of the thumb)</td>
<td>2</td>
</tr>
<tr>
<td>4 to 10 small joints (may also have large joints) (Wrist; metacarpophalangeal, proximal interphalangeal, or 2&lt;sup&gt;nd&lt;/sup&gt; – 5&lt;sup&gt;th&lt;/sup&gt; metatarsophalangeal joints; or interphalangeal joint of the thumb)</td>
<td>3</td>
</tr>
<tr>
<td>&gt;10 joints with at least ≥1 small joint (Sternoclavicular, temporomandibular, or acromioclavicular joints)</td>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Serologic Markers</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative RF and negative ACPA (Results in IU are &lt;ULN for the parameter)</td>
<td>0</td>
</tr>
<tr>
<td>Low positive RF or ACPA (Results in IU are &gt;ULN but &lt;3 times ULN for the parameter)</td>
<td>2</td>
</tr>
<tr>
<td>High positive RF or ACPA (Results in IU are &gt;3 times ULN for the parameter)</td>
<td>3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acute-phase Reactants</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal CRP and normal ESR</td>
<td>0</td>
</tr>
<tr>
<td>Abnormal CRP and/or abnormal ESR (above ULN for the laboratory parameter)</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Duration of Symptoms*</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤6 weeks</td>
<td>0</td>
</tr>
<tr>
<td>&gt;6 weeks</td>
<td>1</td>
</tr>
</tbody>
</table>

*Duration is reported by patients.

ACPA, anti-citrullinated protein antibody or anti-CCP; ACR, American College of Rheumatology; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; IU, international units; RA, rheumatoid arthritis; RF, rheumatoid factor; ULN, upper limit of normal
**Laboratory Tests**

The following tests should be done if a patient is suspected of having RA:

- Acute-phase reactant(s) – ESR and CRP
- Complete blood count (CBC)
- Serologic markers
  - RF (consider RF isotypes)
  - Antinuclear antibodies
  - ACPA
    - High specificity for RA
    - Often associated with more aggressive disease
    - In combination with a positive RF, the diagnosis of RA is virtually certain

A positive RF test is not unique to RA. It is positive in 5% to 8% of the population, and its incidence increases with normal aging. It can also be seen in other autoimmune disorders (such as lupus or Sjögren’s syndrome), in chronic infections (such as endocarditis, TB, or viral hepatitis), and in granulomatous diseases. Rheumatoid factor is positive in approximately 60% to 80% of patients with RA.\(^{36}\)

There are three known isotypes of RF—IgM, IgG, and IgA—that may be present prior to the onset of RA symptoms.\(^{37}\) The IgA isotype is found in 25%, the IgG isotype in 18%, and the IgM isotype in 26% of asymptomatic patients who will develop RA. At the time of diagnosis; IgA, IgG, and IgM isotypes were found in 64%, 57%, and 79% of patients, respectively.\(^{38}\)

Houssien et al.\(^{39}\) reported that patients who tested positive for IgA and IgM isotypes had higher disease activity scores and greater joint damage than those who tested negative for these immunoglobulins. The authors also reported that patients with RA who were positive for the IgA isotype alone (without the IgM isotype) had more severe disease than those positive for only the IgM isotype or for both IgA and IgM. Gioud-Paquet et al.\(^{40}\) also found an association of elevated IgA and IgM with high disease activity (HDA).

Anti-citrullinated protein antibody is highly specific for RA.\(^{41}\) It is associated with more aggressive disease and, when seen in combination with a positive RF, the diagnosis of RA is virtually certain. Both RF and ACPA may be positive before RA symptoms develop.\(^{41,42}\) Patients with active RA can sometimes have normal acute-phase reactants (ESR and CRP).

Antinuclear antibodies are present in about 40% of patients with RA. This test, however, is not specific for RA.

**Patient Assessment**

At the initial visit, the patient should be asked to complete a Patient Global Assessment (PtGA) form, a Routine Assessment of Patient Index Data 3 (RAPID 3) or a Multidimensional Health Assessment Questionnaire (MDHAQ; see Glossary). Irrespective of the form used, it should also be completed at subsequent visits, because serial measurements can assist rheumatologists in defining progress and adjusting treatment.
Due to dysregulated immune function and exposure to immunomodulating medications, patients with RA have an increased risk of infection. Prior to starting pharmacologic therapy, it is important to obtain a detailed vaccination history. All patients with RA treated with biologics or biosimilars should have a pneumococcal vaccination according to the Centers for Disease Control and Prevention (CDC)-recommended schedule, as well as an annual flu vaccination. Rheumatoid arthritis patients with risk factors for a hepatitis B virus (HBV) infection treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), originator biologic disease-modifying antirheumatic drugs (boDMARDs), or biosimilar disease-modifying antirheumatic drugs (bsDMARDs, see Glossary for definitions for all four types of DMARDs) should be vaccinated for HBV, if this has not been done already. The new herpes zoster vaccine (Shingrix) is a non-live subunit vaccine that is more effective than the previous live attenuated vaccine (Zostavax®). As Zostavax contains live virus, it should not be given to patients who are currently treated with biologics, but it may be given prior to starting biologic therapy. Shingrix should not be given to pregnant or breast feeding women. At this time, the CDC does not recommend Shingrix for immunocompromised patients. Additional studies are planned.

**Imaging**

Imaging is an important part of the overall workup of patients with RA. Radiographs are inexpensive and widely available, and currently, X-ray is the initial imaging test of choice. It can be helpful in establishing the diagnosis of RA, particularly in difficult or unclear cases, and it can demonstrate progression of the disease.

Plain radiographs are not used in the classification of RA according to the ACR/EULAR classification system described above, because they are frequently normal in patients with very early disease. However, radiographs can and should be used to establish the diagnosis of RA. For instance, if available, recent X-rays of the hands and feet may be helpful in establishing a diagnosis for a patient who does not score ≥6 points in the ACR/EULAR classification system as some of the available radiographs may demonstrate typical RA erosions; the patient can then be diagnosed with RA.

When using radiographs to diagnose RA, it is important to be precise. In 2013, EULAR published a definition of typical RA erosions to assist physicians in diagnosing patients who do not fulfill the classification criteria but in whom a diagnosis of RA is suspected. To establish the diagnosis of RA based on radiographs of the hands and feet, there must be an erosion (defined as a break in the cortex of bone) of any size in ≥3 different joints from the following list:

- Proximal interphalangeal joints
- Metacarpophalangeal joints
- Metatarsophalangeal joints
- Wrist (counts as one joint)

If a patient meets the classification criteria for RA, baseline radiographs of the hands and feet should be obtained, if not recently performed. The presence of X-ray evidence of erosions at the time of diagnosis is associated with a poor prognosis.

Baseline X-rays (postero-anterior, lateral, and ball-park or Norgaard views) of the hands and three views of the feet should be obtained in all patients with a definite or possible diagnosis of RA. Bone
changes may lag behind symptoms by as much as 6 to 12 months; baseline imaging is important to properly follow these patients.

Ultrasound of the hands and feet can be considered for patients with normal X-rays, because bone erosions may be detected before they are seen on plain films.

If there is suspicion of cervical spine involvement, based on history or clinical evaluation, lateral radiographs of the cervical spine in neutral, flexion, and extension views should be obtained. Magnetic resonance imaging (MRI) of the cervical spine should be pursued in any patient with RA who has radiographic evidence of instability or clinical signs or symptoms of neurological involvement.45

The ACR recommends against the routine use of MRI for the evaluation of inflammatory arthritis.46 United Rheumatology supports this recommendation.

Treatment

It is important that the patient has a clear understanding of the goals of therapy, as well as the risks and benefits of the proposed treatment plan. The goal of treatment for RA is to maximize long-term health-related QoL by controlling symptoms, preventing structural progression, preserving normal function, and improving patient-reported outcomes.

United Rheumatology believes these goals are best accomplished by using the treat-to-target paradigm, with remission as the primary and ultimate clinical goal. Early and aggressive treatment is important because even a brief delay of therapy can adversely affect long-term outcomes. If a clinical remission cannot be achieved because of long-standing disease or comorbidities, low disease activity (LDA) is an acceptable alternative.47

Treatment should be based on accepted, objective, consistently utilized metrics of disease activity. Drugs should be adjusted if the established targets are not achieved within the expected timeframe and should always be directed by a rheumatologist or under the supervision of a rheumatologist.

With the currently available drugs, it is possible to achieve remission in many patients. If treatment is started early, some patients may have no or minimal joint damage or disability. Without adequate treatment, approximately 60% of patients develop significant and irreversible joint damage within the first 2 years of diagnosis.48 Progressive joint damage is often faster early in the course of the disease,49 so that early and aggressive treatment is essential to minimize joint damage. Studies have demonstrated that this treatment approach is associated with better therapeutic outcomes including a decrease in disease activity score, more favorable radiographic outcomes, and improvement in physical function and QoL.50
A poor outcome increases with the number of risk factors such as:\textsuperscript{51, 52}

- HDA
- Elevated acute-phase reactants such as ESR and CRP
- High swollen joint count
- Auto-antibodies at high levels (RF and ACPA)
- Extra-articular disease
- Early erosions
- Moderate disease activity (MDA) to HDA after treatment with methotrexate (MTX) for at least 3 months, with therapeutic blood levels of the drug
- Multiple comorbidities

When treating patients with RA, objective measures of disease activity should be used. The most common measures for RA are based on clinical, laboratory, and imaging results. Currently, several validated tools are available. These include the Disease Activity Score 28 (DAS28), Clinical Disease Activity Index (CDAI), and the RAPID 3.

Although all of these tools are commonly used, United Rheumatology favors a composite score (that includes swollen and tender joints) such as the CDAI rather than evaluator-only or patient-only derived measures. The DAS28 has been reported to be insufficiently stringent for consistent identification of remission.\textsuperscript{53} In a study involving 864 patients with RA receiving MTX monotherapy, DAS28 remission was comparable to remission based on the CDAI scores only if the patient did not have any residual swollen joints. The CDAI allows for a maximum of two swollen joints in remission but, according to the authors, DAS28 allowed for more than twelve swollen joints when the patient was said to be in remission.\textsuperscript{54} Therefore, United Rheumatology supports the use of the CDAI as the best-validated method for determining disease activity in RA.

The CDAI scoring systems is built around five core disease-activity parameters, which include the following:

- Tender joint count (based on evaluation of 28 joints)
- Swollen joint count (based on evaluation of 28 joints)
- PtGA
- Patient Health Assessment
- Physician Global Assessment

Scores range from 0 to 76 (Table 3). A calculator for the CDAI can be found in the Appendix.

\textit{Table 3. Disease activity categories according to the CDAI scoring system}

<table>
<thead>
<tr>
<th>Disease Activity</th>
<th>Scores</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remission</td>
<td>≤2.8</td>
</tr>
<tr>
<td>LDA</td>
<td>≤10</td>
</tr>
<tr>
<td>MDA</td>
<td>&gt;10.0 to 22.0</td>
</tr>
<tr>
<td>HDA</td>
<td>&gt;22.0</td>
</tr>
</tbody>
</table>

CDAI, Clinical Disease Activity Index; LDA, low disease activity; MDA, moderate disease activity; HAD, high disease activity
There is no single gold standard disease-activity laboratory marker for RA. Currently, ESR and CRP are used as markers of inflammation, although they are not specific for RA. In addition, isotypes of RF may be helpful, as discussed above. A study by Keenan et al. that included 188 patients with RA found no strong relationship between ESR and CRP values and other measures of disease activity and suggested that these acute-phase reactants had limited usefulness for making treatment decisions. More recently, the Vectra® DA test has become a validated serologic marker of disease activity. High Vectra DA scores have been predictive of radiographic disease progression. A baseline Vectra DA can be considered in patients with RA, especially if this test will be used in conjunction with other data to monitor response to therapy or to support tapering of medications in a patient who has been in remission.

In remission, patients should have no evidence of radiographic progression and might even show healing of erosions.

When a validated scoring system is used and treatment adjusted, based on the results of an objective measure of disease activity, clinical outcomes improve. For patients with HDA or MDA, scores should be calculated at 1- to 3-month intervals; in those with sustained remission or LDA, scores should be calculated at 6- to 12-month intervals. The measures used at each visit should always be the same to obtain an objective assessment of changes in disease activity. If desired, more than one measure can be calculated at each visit.

The consistent use of RA disease measurements is essential for quantitative comparisons of disease activity over time and for gauging response to treatment.

**Pharmacologic Therapy Overview**

Aggressive drug therapy should begin early. Disease-modifying antirheumatic drugs (DMARDs) are a staple in the treatment of patients with RA (Table 4).

Until the desired treatment target is achieved, drug therapy should be assessed and adjusted as often as required. Disease activity should be calculated at each visit, and medications adjusted appropriately.

Unfortunately, noncompliance with prescribed drugs is a significant problem in the management of patients with RA. A recent study by Kan et al. retrospectively reviewed electronic health records (EHRs) from more than 50 provider organizations in the US and looked at pharmacy claims, provider claims, and facility claims. The authors identified patients who were newly prescribed either oral or injectable MTX, a biologic, or tofacitinib. Primary nonadherence was defined as a new prescription of MTX or a new prescription or infusion of biologics or tofacitinib written by a physician (as recorded in EHRs) but not filled or administered within 2 months for MTX or 3 months for biologics/tofacitinib (based on claims). Approximately 36.8% of the MTX group was nonadherent within 2 months of the prescription and 40.6% of the patients in the biologic/tofacitinib group were nonadherent.

Irrespective of the pharmacologic therapy prescribed, patients must be counselled regarding the importance of adherence with the medical program, especially since noncompliance may result in poor outcomes that could have been avoided. The importance of compliance should be re-enforced
at every visit. As part of this discussion, a behavioral agreement between the patient and the physician may be considered for new patients as a way to encourage adherence with medications.

Table 4. Drugs used in the management of RA

<table>
<thead>
<tr>
<th>Drug</th>
<th>Route of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>csDMARDs</strong></td>
<td></td>
</tr>
<tr>
<td>Methotrexate (Rheumatrex&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>Oral</td>
</tr>
<tr>
<td>Methotrexate (Rasuvo&lt;sup&gt;®&lt;/sup&gt;, Otrexup™)</td>
<td>SQ</td>
</tr>
<tr>
<td>Leflunomide (Arava&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>Oral</td>
</tr>
<tr>
<td>Sulfasalazine (Azulfidine&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>Oral</td>
</tr>
<tr>
<td>Hydroxychloroquine (Plaquenil&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>Oral</td>
</tr>
<tr>
<td>Azathioprine (Imuran&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>boDMARDs</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Non-TNF inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>Abatacept (Orencia&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>IV or SQ</td>
</tr>
<tr>
<td>Rituximab (Rituxan&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>IV</td>
</tr>
<tr>
<td><strong>TNF inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>Adalimumab (Humira&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>SQ</td>
</tr>
<tr>
<td>Certolizumab pegol (Cimzia&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>SQ</td>
</tr>
<tr>
<td>Etanercept (Enbrel&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>SQ</td>
</tr>
<tr>
<td>Golimumab (Simponi&lt;sup&gt;®&lt;/sup&gt; and Simponi&lt;sup&gt;®&lt;/sup&gt; Aria)</td>
<td>SQ and IV</td>
</tr>
<tr>
<td>Infliximab (Remicade&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>IV</td>
</tr>
<tr>
<td><strong>IL-6 inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>Tocilizumab (Actemra&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>IV or SQ</td>
</tr>
<tr>
<td>Sarilumab (Kevzara&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>SQ</td>
</tr>
<tr>
<td><strong>bsDMARDs</strong></td>
<td></td>
</tr>
<tr>
<td>Erelzi (reference drug: etanercept-szzs [Enbrel&lt;sup&gt;®&lt;/sup&gt;])</td>
<td>SQ</td>
</tr>
<tr>
<td>Amjevita (reference drug: adalimumab [Humira&lt;sup&gt;®&lt;/sup&gt;])</td>
<td>SQ</td>
</tr>
<tr>
<td>Inflectra (reference drug: infliximab [Remicade&lt;sup&gt;®&lt;/sup&gt;])</td>
<td>IV</td>
</tr>
<tr>
<td>Renflexis (reference drug infliximab [Remicade&lt;sup&gt;®&lt;/sup&gt;])</td>
<td>IV</td>
</tr>
<tr>
<td><strong>tsDMARDs (JAK inhibitors)</strong></td>
<td></td>
</tr>
<tr>
<td>Tofacitinib (Xeljanz&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>Oral</td>
</tr>
<tr>
<td>Baricitinib (Olumiant&lt;sup&gt;®&lt;/sup&gt;)</td>
<td>Oral</td>
</tr>
<tr>
<td><strong>Corticosteroids</strong>&lt;sup&gt;*&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Short term</td>
<td>Oral, IM, or IV</td>
</tr>
</tbody>
</table>

*Short-term corticosteroids are taken for <3 months.

United Rheumatology does not recommend the use of bsDMARDs for patients already in good control with csDMARDs or boDMARDs or a combination of csDMARDs and boDMARDs.

boDMARDs, biologic disease-modifying antirheumatic drugs; bsDMARDs, biosimilar disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; IL-6, interleukin 6; IM, intramuscular; IV, intravenous; JAK, Janus kinase; SQ, subcutaneous; tsDMARD, targeted synthetic disease-modifying antirheumatic drug; TNF, tumor necrosis factor
Before pharmacologic therapy is initiated, laboratory tests, including but not limited to the following, should be considered:

- CBC with differential count
- Liver function test
- Electrolytes
- Blood urea nitrogen and creatinine
- Glomerular filtration rate
- TB testing for patients starting boDMARDs, bsDMARDs, or tsDMARDs

When selecting pharmacologic therapy, existing comorbidities must be considered. Treatment modifications may be required in patients with a history of (but not limited to) any of the following:

- Congestive heart failure Class 3 or 4 (TNF inhibitors should not be used until adequate restoration and stabilization of cardiac function is achieved.)
- Active HBV infection
- Prior exposure to HBV – hepatitis C virus infection
- Previous serious infections
- Previously treated or untreated malignancy
- Skin cancer of any type
- Previously treated lymphoproliferative disorder
- Renal disease
- Anemia of chronic disease
- Thrombocytopenia
- Leukopenia
- Human immunodeficiency virus

All patients who will be treated with hydroxychloroquine should have a complete baseline ophthalmologic evaluation within the first year of starting therapy. Annual ophthalmologic examinations should be obtained while the patient remains on this drug. One of the major complications associated with hydroxychloroquine therapy is the development of problems with the cornea and/or macula of the eye. The cornea can develop cornea verticillate which is usually reversible after stopping the drug. A more serious potential problem is the development of pigment deposits in the macula resulting in irreversible vision loss.

Physicians must also be aware of possible drug interactions with other medications taken by the patient.

**Initial Treatment of DMARD-naïve Patients**

For DMARD-naïve patients with RA, csDMARD monotherapy should be started as soon as possible. Unless contraindicated, MTX, taken orally or subcutaneously, is the initial drug of choice (Figure 1).

A 2013 Cochrane review reported that the use of folic or folinic acid by patients taking MTX for RA can reduce some of the adverse effects of the drug; including but not limited to nausea, abdominal pain, abnormal liver function, and oral ulcers. The report also stated that taking either folic or folinic acid helped patients to continue taking MTX for the management of their RA. Taking either of these
supplements did not appear to decrease the efficacy of MTX. Every patient taking MTX, regardless of whether orally or subcutaneously, should be taking folic or folinic acid.

**Methotrexate (MTX)**

Based on the 2016 EULAR recommendations, MTX can be given either orally or subcutaneously. The ACR briefly addresses the subcutaneous administration of MTX (SQ MTX) in the 2015 update of their RA guideline but does not expand on its use. Most patients are started on 10 mg to 15 mg of oral MTX per week. If there is no improvement in disease activity within a few weeks, then the dose should be rapidly escalated up to 25 mg per week until there is either an adequate response (remission or LDA) or the maximum or highest tolerable dose has been reached. For patients on ≥15 mg of oral MTX per week, split-dosing should be considered, because this can increase the bioavailability of the drug. Split doses should be given 8 hours apart. Renal and liver function tests, and CBC results should be closely followed in all patients on MTX, regardless of dose or route of administration. In some cases, it may be necessary to change medications based on the results of hematologic, renal, and/or liver function tests. Patients should be monitored for uncommon but potentially serious adverse events, including pulmonary toxicity. Monitoring also requires thorough patient education relating to side effects and adverse events. Methotrexate must be given for 3 months before maximum efficacy can be determined.

Although MTX is approved in the US for both oral and subcutaneous use, the latter route, which has been shown to be very effective and less costly than biologics or tsDMARDs, is under-utilized. In one study of only about 38% of commercially insured and Medicare patients received doses of oral MTX exceeding 20 mg per week. This study also found that patients who advanced to a biologic rarely had a trial of SQ MTX.

Only about 70% of orally administered MTX is absorbed. The efficacy of MTX can be limited by several factors; however, the most important one is inadequate absorption, especially at doses over 15 mg per week. It has been well documented that the bioavailability of oral MTX is not as reliable as that of SQ MTX. Increasing the oral dose to augment the amount of drug available also increases adverse events and toxicity, which is an important limiting factor for the orally administered drug.

In a study by Hazlewood et al., SQ MTX was associated with a lower failure rate (49%) than with oral administration (77%). There was no difference in treatment failure due to toxicity between the two routes of administration, but there was a significant difference in failure secondary to lack of efficacy, which was higher in patients treated orally. These findings were consistent with those of an earlier study in which SQ MTX had been shown to be more effective than oral administration at the same dose.

A retrospective review of 196 patients with RA who had been changed from oral to SQ MTX was reported in 2014. Half of the patients in this study were changed to SQ MTX, because they had an inadequate response to oral MTX. Of those who were changed to SQ MTX, approximately 44% did not tolerate the drug orally. Of this group, 83% continued with SQ MTX for 1 year, 75% for 2 years, and 47% were still using SQ MTX at 5 years. Less than 10% of this group required a biologic in addition to MTX during the first 2 years of the study because of an inadequate response.
Rohr et al.\(^6\) looked at a large population of DMARD-naive RA patients diagnosed in 2009 and 2012. The patients were followed for 3 (2012 group) to 5 years (2009 group). The authors looked at initial treatment in these patients and for any evidence of change in prescribing habits of their providers.

In the 2009 group, 25% received a biologic before a trial of MTX; 7% were initially started on SQ MTX, and 68% were initially started on oral MTX. Of those started on oral MTX, 44% remained on it for the 5 years of the study. The average dose of MTX was 15.3 mg before either a biologic was introduced or a change to SQ MTX was initiated. In 41% of the patients who had a change in medication, the change occurred in within the first 3 months after starting MTX. Interestingly, 72% of the group that switched from oral MTX to SQ MTX remained on it for the duration of the study. The 2012 group had a modest increase in oral MTX dose (15.9 mg) before changing treatment. This group had a small but significant increase in their use of SQ MTX (16% vs 13%).

The authors concluded that treatment of RA patients with oral MTX may be suboptimal, both in dose and duration, before a change is initiated. They also reported that a significant number of patients started on or changed to SQ MTX did NOT require biologic therapy.

In 2011, the Canadian Rheumatology Association published recommendations for pharmacological management of RA.\(^6\) Recommendation 11 (Page 6) states the following:

> Dosing of methotrexate (MTX) should be individualized to the patient (IV).

> MTX should be started oral or parenteral and titrated to a usual maximum dose of 25 mg per week by rapid dose escalation. In patients with an inadequate response or intolerance to oral MTX, parenteral administration should be considered (I). (Level I, IV, Strength A).

United Rheumatology strongly encourages the use of SQ MTX, either initially or if the response to oral MTX is insufficient, to achieve remission or LDA. Subcutaneous methotrexate has been demonstrated to achieve better bioavailability than oral MTX, without an increase in adverse effects.

Whenever conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are started or changed, short-term steroids should be considered according to the 2016 update of the EULAR recommendations.\(^5\) Steroids can be administered orally, as a single intramuscular injection, or as a single intravenous infusion. If oral short-term steroids are used, they should be tapered as rapidly as possible (within 3 months). In some patients, it may not be possible to completely stop oral steroids; however, the dose should be as low as possible.\(^5\) In the 2015 update of their RA treatment guidelines, the ACR suggests that patients with ≤6 months of symptoms prior to starting csDMARDs (usually monotherapy with MTX) can also be started on low-dose steroids (≤10 mg of prednisone or equivalent) if they have MDA or HDA.\(^5\) For patients who have failed csDMARD monotherapy (usually MTX), have MDA or HDA, and will start combination csDMARDs with either a boDMARD or, if appropriate, a bsDMARD, added to MTX monotherapy, short-term (<3 months) steroids should be considered.\(^5\)

If MTX is contraindicated or not tolerated, then leflunomide at 20 mg daily and/or sulfasalazine at up to 3 g daily and/or hydroxychloroquine can be considered as monotherapy or in combination (Figure 2).\(^5\)
Figure 1. Initial pharmacologic management of DMARD-naïve patients with RA and no contraindication to MTX

*In some patients with comorbidities, LDA may be the treatment target; when LDA is reached, continue the same regimen and do not consider tapering. In other patients with very significant or multiple comorbidities, it may not be possible to escalate treatment to reach LDA.

When using MTX, folic acid supplementation at 1 mg to 5 mg per day is needed. Folinic acid at an equivalent dose may also be used.

Admin, administration; CDAI, Clinical Disease Activity Index; DMARD, disease-modifying antirheumatic drug; LDA, low disease activity; mo., months; MTX, methotrexate; RA, rheumatoid arthritis
Figure 2. Initial pharmacologic management of DMARD-naïve patients with RA and a contraindication to MTX

*In some patients, LDA is the treatment target; when LDA is reached, continue the same regimen and do not consider tapering.

boDMARD, biologic originator disease-modifying antirheumatic drug; bsDMARD, biosimilar disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; DMARD, disease-modifying antirheumatic drug; LDA, low disease activity; mo., months; MTX, methotrexate; pts., patients; RA, rheumatoid arthritis; tsDMARD, target-specific disease-modifying antirheumatic drug
In DMARD-naïve patients with early RA, the response to treatment should be carefully re-evaluated at 3 months using an objective measure (CDAI). Based on their pooled analysis of clinical trial data, Aletaha et al.\textsuperscript{69} considered 3 months after initiating treatment to be a critical decision point. They reported that patients demonstrating an improvement of at least 50% in disease activity had a very good likelihood of reaching remission in another 3 months on the current dose. Patients who demonstrated a less-than-50% improvement in their disease activity scores were not likely to achieve remission after an additional 3 months on the same medication regimen.

After the initiation of csDMARD therapy, the patient should be seen as often as necessary for re-evaluation and dose adjustment or until a stable drug regimen is established. The initial trial of oral MTX should last at least 3 months to see the maximum effect of the drug. During that time, the dose should be escalated rapidly until either the patient reaches remission by CDAI, the maximum tolerated dose is reached, or an oral dose of 25mg a week is reached.

**Patients with an Adequate Response to Methotrexate (MTX) at 3 Months**

For patients who have reached either remission or LDA at the end of 3 months, the dose and route of administration of MTX should not be adjusted. These patients should be monitored for any change in disease activity, flares, or signs of drug toxicity that may require modification of drug therapy.

In general, once a patient is stable on MTX, re-evaluation is usually needed on a quarterly basis. For those with no comorbidities, less frequent evaluation may be appropriate. Repeat disease activity scoring should be performed at each visit, and drug doses should be adjusted based on a combination of disease activity score and clinical evaluation.

The importance of reaching a durable state of remission and the need for continued follow-up should be stressed to all patients at every visit. Unfortunately, **30% to 40% of patients may not have an adequate response to MTX\textsuperscript{70}** despite a trial of SQ MTX.

**Patients with an Inadequate Response to Methotrexate (MTX) at 3 Months**

Patients who have achieved an improvement of at least 50% in disease activity but are not yet in remission or at LDA after 3 months of MTX have a very good chance of achieving that target at the end of another 2 to 3 months using the same dose and route of administration, or they may be changed to SQ MTX at the same dose to improve bioavailability of the drug.

United Rheumatology recognizes that there are patients who have not completely reached the 50% improvement target but are close to it at the end of 3 months. Additional consideration may be given to the trajectory of improvement for these individuals. For example, if a patient is close to the 50% threshold of improvement in CDAI, and there is more improvement toward the end of the 3-month trial, the provider may decide to maintain this patient on the current medication level for another 2 months as he/she may not yet have reached a steady state with MTX; alternatively, the provider may decide to switch the patient to SQ MTX at the same dose. If this patient does not reach remission or LDA at the end of the additional
2 to 3 months, a boDMARD or bsDMARD (if appropriate), or a tsDMARD (Figure 3) should be started. Methotrexate should be continued, if appropriate.

A patient on oral MTX who has reached slightly more than a 50% improvement in disease level at the 3-month mark but with a considerably slowed rate of improvement in the last few weeks may be less likely to reach the target of remission or LDA in another 2 to 3 months at the same dose. The provider may consider keeping the patient on the same dose of MTX for another 2 to 3 months or switching to subcutaneous MTX at the same dose for 2 to 3 months and then re-evaluating disease activity. If there is a remission or LDA, the patient may be kept on the same dose and route of administration of MTX. If remission or LDA has not been reached, the patient should be changed to a boDMARD or bsDMARD (if appropriate), or a tsDMARD (Figure 3) should be started. Methotrexate should be continued, if appropriate.

For patients who have achieved a less-than-50% improvement in disease activity at the end of 3 months of oral MTX, measuring the MTX polyglutamate (MTX PG) level should be considered (see discussion below). A MTX PG level <20 nmol/L may indicate that the patient is either not compliant with the drug regimen or not adequately absorbing or metabolizing the drug.

**Methotrexate Polyglutamate (MTX PG) Levels**

Methotrexate is the initial drug of choice for treating DMARD-naïve patients with RA. Methotrexate is a folate antagonist, and the doses required to obtain an adequate response (remission or LDA) vary from patient to patient and therefore are unpredictable. Methotrexate may also be associated with numerous adverse events such as but not limited to nausea, vomiting, fatigue, hair loss, elevated liver function test results, rising creatinine levels, infection, and cytopenias.

After MTX is ingested or parenterally administered, the serum concentration falls rapidly. The biochemical reactions that occur when MTX enters a cell are very complex. If the reader is interested in more information on this subject he/she is referred to the following:

- Kremer JM. Toward a better understanding of methotrexate.72
- Goodman S. Measuring methotrexate polyglutamates.70

When MTX enters a cell, it forms polyglutamate (PG). Many different forms of MTX PG are synthesized over time. The MTX PG test measures the level of MTX PG in circulating erythrocytes. The results are reported as one of three categories: therapeutic (>60 nmol/L), intermediate (20 to 60 nmol/L), or subtherapeutic (<20 nmol/L).71, 73 According to Exagen Diagnostics, one of the providers of this test, patients falling into the subtherapeutic group were three times more likely to have a poor response to MTX than those with a level >20 nmol/L; patients with a MTX PG level >60 nmol/L were five times more likely to have a good response to MTX than those with a level of ≤60 nmol/L.73

**Patients with Therapeutic Methotrexate Polyglutamate (MTX PG) Levels**
A patient who has a therapeutic level of MTX PG at 3, 5, or 6 months but failed to reach remission or LDA should not continue with MTX monotherapy. This patient should be switched to a boDMARD, bsDMARD, or tsDMARD. Methotrexate may be continued, if appropriate.

Patients with a less-than-50% improvement in disease activity level at the end of the first 3 months despite a therapeutic MTX PG level should also be started on a boDMARD or bsDMARD (if appropriate), or a tsDMARD (Figure 3). Methotrexate should be continued, if appropriate.

**Patients with Subtherapeutic Methotrexate Polyglutamate (MTX PG) Levels**

If, at the 3-month decision point, response to oral MTX is inadequate by CDAI and the MTX PG level is subtherapeutic, switching the patient to SQ MTX should be strongly considered (see discussion on SQ MTX below) (Figure 4). If there is concern that the patient is non-compliant, this should also be addressed and a second trial of oral can be considered or the patient can be switched to SQ MTX.

Two to 3 months after switching to SQ MTX, the patient should be re-evaluated. If there is less-than-50% improvement in the disease activity score and the patient has been taking the medication, a boDMARD or bsDMARD (if appropriate), or a tsDMARD should be started. Methotrexate should be continued, if appropriate.

If the patient has reached remission or LDA at the end of the additional 2 to 3 months of oral or SQ MTX, the current medication regimen should be maintained. These patients should be monitored for any change in disease activity, flares, or signs of drug toxicity that may require modification of drug therapy.

Patients achieving remission or LDA with a subtherapeutic MTX PG level should be maintained on the dose and route of administration that has achieved the treatment target. They should be followed for evidence of increasing disease activity, flares, and signs of MTX toxicity.
Figure 3. Pharmacologic management of patients with RA and therapeutic levels of MTX PG and either <50% improvement in CDAI after 3 months of treatment with MTX or failure to attain remission after 6 months of MTX

boDMARD, biologic originator disease-modifying antirheumatic drug; bsDMARD, biosimilar disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; DMARD, disease-modifying antirheumatic drug; mo., months; HAD, high disease activity; MDA, moderate disease activity; MTX, methotrexate; MTX PG, methotrexate polyglutamate; RA, rheumatoid arthritis; tsDMARD, target-specific disease-modifying antirheumatic drug
Figure 4. Pharmacologic management of patient with RA and subtherapeutic levels MTX PG who have had either <50% improvement in CDAI after 3 months of treatment with oral MTX or failure to attain remission after 5 months of oral MTX.

For patients treated initially with SQ MTX with subtherapeutic levels of MTX PG, go to Figure 6.

*In some patients, LDA is the treatment target; when LDA is reached, continue the same regimen and do not consider tapering.
boDMARD, biologic originator disease-modifying antirheumatic drug; bsDMARD, biosimilar disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; DMARD, disease-modifying antirheumatic drug; mo., months; MTX, methotrexate; MTX PG, methotrexate polyglutamate; PG, polyglutamate; RA, rheumatoid arthritis; tsDMARD, target-specific disease-modifying antirheumatic drug
**Patients with Intermediate Methotrexate Polyglutamate (MTX PG) Levels**

Management of patients with MTX PG levels in the intermediate category range after 3 months of oral MTX is not as clear as for those in the subtherapeutic or therapeutic range who have not reached remission or LDA. Those who fall into the intermediate range of MTX PG and have reached remission or LDA should be kept on the current dose and administration route and be monitored carefully for evidence of flares or an increase in disease activity.

There is no conclusive evidence that higher MTX PG levels correlate with better patient response, especially in the intermediate range. Approximately one third of patients will never respond to MTX, regardless of dose or mode of delivery, and regardless of the MTX PG level. According to Goodman, “There is no absolute correlation of MTX PG levels with beneficial effect, although efficacy is more likely at higher levels. Patients with MTX PG levels above 60 nmol/L are more likely to have a therapeutic benefit than those patients with lower levels. There is considerable overlap between the groups. Moreover, the lag to steady state equilibrium diminishes the timeliness necessary if this were to be used to guide dose escalations.” (Page S24).

Dervieux et al. stated that well designed prospective studies are needed to determine how MTX PG may be used to determine the effectiveness of MTX in a particular patient. In addition, pharmacogenetic factors must be looked at to understand how these might influence an individual’s response to MTX.

There have been several published studies trying to determine if higher levels of MTX PG correlate with better response to MTX. The results are inconsistent. The demographics and study designs are highly variable, and these two factors may be partly responsible for the inconsistent results.

In a study published by Murosaki et al. in 2017, the authors state that MTX PG may have the potential to assist providers in determining the efficacy of MTX and help them to determine doses and mode of administration. However, although this study was promising, even the authors acknowledge that the protocol for the study was not followed rigorously but that, instead, it was conducted under the conditions of routine clinical practice and that more rigorous studies are needed before MTX PG can be used to determine dosing. Another study published in 2013, demonstrated that higher MTX PG levels were associated with LDA, after 3 months and continued to improve at 6 months and 9 months. No specific correlations with disease activity scores and MTX PG levels were provided. Additional studies were recommended by these authors as well.

A 76-week study with 79 MTX-naïve patients using a more rigorous protocol than Murosaki et al. found that dose escalation of MTX resulted in higher levels of MTX PG and a decrease in disease activity scores. The MTX PG concentrations were found to be affected by both body mass index and serum albumin level. The researchers found that patients with a good EULAR response at 12 and 24 weeks had higher MTX PG levels than those who had not achieved a good response, but they were not able to provide guidance as to which numbers were significant. Some of their patients had a poor response despite increased doses of MTX. In addition, some patients experienced adverse events that required either stopping MTX or decreasing the dose. The authors noted that “despite the dosages of MTX used being largely similar, the MTX-PG concentrations in our patients were markedly higher than those observed in other studies from Europe or the USA.” (Page 8). This demonstrates that patient characteristics can significantly affect
MTX PG levels and the response to MTX, suggesting that studies performed on different patient populations may not be comparable.

Patients in the intermediate group who have not reached remission or LDA, may benefit from a change to SQ MTX, because this has the potential of increasing the bioavailability of the drug. If, after 2 to 3 months of SQ MTX, the patient is in remission or has LDA, then the same dose and administration route should be continued, regardless of the MTX PG level. For those patients who do not reach an acceptable disease activity level after 2 to 3 months of SQ MTX, adding a biologic, biosimilar, or tsDMARD should be considered.

*When Methotrexate Polyglutamate (MTX PG) Levels Are Not Feasible or Available*

If, at the end of 3 months on oral MTX, a serum MTX PG level is not available, and the patient has not reached either a clinical remission or LDA by CDAI, then a change to SQ MTX should be strongly considered (Figure 5).

If there is a less-than-50% improvement in disease activity after 2 to 3 months of SQ MTX, the patient should be switched to either a boDMARD or, if appropriate, a bsDMARD or a tsDMARD. Methotrexate should be continued as appropriate. If the patient has an improvement of at least 50% in disease activity level after 2 to 3 months of SQ MTX, then the patient should be kept on the same drug regimen and re-evaluated in another 2 to 3 months. If the patient has not achieved remission at the end of the second 2 to 3-month trial, then the patient should be switched to a boDMARD or, if appropriate, a bsDMARD or a tsDMARD. Methotrexate should be continued as appropriate.
• DMARD-naive  
• No contraindication to MTX

Start oral MTX at 10 mg/week  
+ Short-term steroids*

If inadequate response, increase MTX dose rapidly until
• An adequate response (remission or LDA)  
OR
• 15-35 mg/week orally or highest tolerable dose has been reached  
(at these oral dose levels, split-dosing should be considered)

No remission or LDA by CDAI after 3 mo. of oral MTX

MTX PG not done or not available

• Change to SQ MTX and escalate dose, as appropriate,  
up to 25 mg/week  
• If subcutaneous MTX was used initially, go to  
Figures 6 and 7

Remission by CDAI after 2 mo. For patients with significant comorbidities, LDA is acceptable

Continue current treatment regimen

Durable remission*

Maintain current therapy  
OR  
Consider tapering in appropriate patients

See Figures 6 and 7

No remission or LDA by CDAI after 2 mo.

Consider measuring MTX PG levels and counsel patient regarding compliance

MTX PG level  
20 to >60

boDMARDs ± MTX  
OR  
bsDMARDs ± MTX  
OR  
tsDMARD ± MTX

See Figures 6 and 7

b0DMARD ± MTX  
OR  
bsDMARD ± MTX  
OR  
tsDMARD ± MTX

MTX PG level <20

Consider non-compliance  
See text, if taking medication at proper dose
Figure 5. Pharmacologic management of patients with RA and no MTX PG levels with either <50% improvement in CDAI after 3 months of treatment with oral MTX or failure to attain remission after 5-6 months treatment with oral MTX.

For patients treated initially with SQ MTX with subtherapeutic levels of MTX PG, go to Figure 6.

*In some patients, LDA is the treatment target; when LDA is reached, continue the same regimen and do not consider tapering.

boDMARDs, biologic originator disease-modifying antirheumatic drugs; bsDMARDs, biosimilar disease-modifying antirheumatic drugs; CDAI, Clinical Disease Activity Index; DMARD, disease-modifying antirheumatic drug; MDA, mo., months; MTX, methotrexate; MTX PG, methotrexate polyglutamate; LDA, low disease activity; PG, polyglutamate; RA, rheumatoid arthritis; tsDMARD, target-specific disease-modifying antirheumatic drug
**Patients Receiving Subcutaneous Methotrexate (SQ MTX) Initially**

If, at the 3-month decision point, there has been an improvement of at least 50% in disease activity score (based on CDAI), the dose may be maintained for an additional 3 months. At the end of a total of 6 months, many patients will have reached the treatment target of remission or LDA. If remission is not achieved at the end of a total of 6 months, then a boDMARD or bsDMARD (if appropriate), or a tsDMARD should be started and MTX continued as appropriate. The considerations of the improvement trajectory described above can also be applied to this patient group.

In patients who have shown a less-than-50% improvement in disease activity score (based on CDAI) at the end of 3 months, a boDMARD or bsDMARD (if appropriate), or a tsDMARD should be started and MTX continued as appropriate.

**Patients with a Contraindication to Methotrexate (MTX)**

For patients with LDA or a contraindication to MTX, who received leflunomide, hydroxychloroquine, or sulfasalazine but did not achieve remission at the 3-month decision point, the use of a boDMARD or bsDMARD (if appropriate), or a tsDMARD should be considered (Figure 2).

**Treatment with boDMARDs, bsDMARDs, or a tsDMARD**

If disease activity remains unacceptably high despite optimizing oral or SQ MTX (possibly in combination with short-term steroids) for an adequate time interval, then a boDMARD or bsDMARD (if appropriate), or a tsDMARD should be started. In general, the combination of MTX with a biologic is more effective than a biologic alone. However, in some cases, monotherapy with a biologic or tsDMARD is appropriate. The patient should be re-evaluated in 3 months and, if the target is achieved, the treatment should be continued (Figure 6).

If after 3 months of a biologic the patient still fails to achieve the treatment target then a change in medication should be made. If the second-choice boDMARD or bsDMARD (if appropriate), or tsDMARD also fails to achieve the treatment target, a different class of boDMARD, bsDMARD, or a tsDMARD should be tried until a combination is found that achieves the lowest disease activity score possible, with the ideal target remaining remission or LDA (Figure 7).

The drugs used for the treatment of RA have been associated with a number of potentially serious adverse events. Physicians should be familiar with the FDA-approved package inserts for the medications listed in Table 4,78-81 and with the management of potential complications.

Patient adherence to medication is critical for achieving the targeted outcome of remission or LDA. Some of the biologics can be self-administered by the patients at home. Drugs that are administered intravenously should be given at an in-office infusion center under the direct supervision of a rheumatologist. Intravenous infusions prevent missed doses and assure compliance. When infusions are given, the provider must be familiar with known adverse events and their management; and with contraindications such as allergies, current infections, or congestive heart failure. Because there are many
potentially serious infusion reactions, United Rheumatology considers home infusions to be unsafe and not in the best interest of the patient.

When a patient requires a biologic (boDMARD or bsDMARD) or a tsDMARD, United Rheumatology believes that the decision of which drug is the most appropriate choice should be made in consultation with the patient.

United Rheumatology does not support changing a patient who has attained remission or LDA on a boDMARD or tsDMARD to treatment with a bsDMARD. At this time, the bsDMARDs recently approved by the FDA are not considered to be interchangeable with the reference biologic.

United Rheumatology does not support the requirement to change medications in a stable patient (durable remission or LDA) when health insurance coverage changes. This can put a stable patient at risk for flares and the possibility of failure to achieve or regain remission or LDA.

NOTE: In general, a boDMARD (or bsDMARD, if appropriate) + methotrexate is more effective than a boDMARD alone; however, some biologics may be used as monotherapy.
Figure 6. Pharmacologic management of patients with RA who failed oral or parenteral MTX, leflunomide or hydroxychloroquine, or sulfasalazine but had an adequate response to either a boDMARD, bsDMARD, or a tsDMARD

*In some patients, LDA is the treatment target; when LDA is reached, continue the same regimen and do not consider tapering.

boDMARD, biologic originator disease-modifying antirheumatic drug; bsDMARD, biosimilar disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; MTX, methotrexate; RA, rheumatoid arthritis; tsDMARD, target-specific disease-modifying antirheumatic drug
Figure 7. Pharmacologic management of patients with RA who failed conventional DMARDs and did not have an adequate response to combination DMARDs or a biologic

*In some patients, LDA is the treatment target; when LDA is reached, continue the same regimen and do not consider tapering.*

boDMARD, biologic originator disease-modifying antirheumatic drug; bsDMARD, biosimilar disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; mo., months; MTX, methotrexate; RA, rheumatoid arthritis; tsDMARD, target-specific disease-modifying antirheumatic drug
Monitoring

Until the desired treatment target is achieved, drug therapy should be continually assessed, initially at fairly frequent intervals. Drug doses or combinations should be appropriately adjusted until remission or the lowest disease activity possible is reached. A CDAI score, MDHAQ or RAPID3, PtGA (only if MDHAQ or RAPID3 are not done), and Physician Global Assessment should be completed at each visit. Some patients with HDA scores and/or comorbidities may require more frequent monitoring, calculation of disease activity scores, and adjustment of medications. Once remission or LDA is reached, patients are usually seen every 3 to 6 months. However, if patients experience any change in symptoms or develop flares, they should be seen as soon as possible.

In stable patients, the MDHAQ or RAPID3, and PtGA (only if MDHAQ or RAPID3 are not done) should be completed at each visit, together with the CDAI and Physician Global Assessment. Monitoring of blood tests should be performed as needed, based on a patient’s overall medical status and the medications used.

Annual radiographic evaluation is not necessary for patients with normal initial X-rays and remission or LDA. In these patients, X-rays can be performed every 2 to 4 years. If erosions are seen on initial X-rays, an annual radiographic examination of the hands and feet can be used to determine disease progression. If baseline X-rays are normal, regardless of disease activity, ultrasound may be helpful in detecting erosions or clinically undetected synovitis.

Ultrasound is increasingly used in the diagnosis and management of RA. However, there are currently no firm guidelines that address either the frequency of ultrasound or its use in scoring of disease activity. According to EULAR, ultrasound may be helpful in establishing a diagnosis of RA in a patient who does not meet RA classification criteria by demonstrating active synovial inflammation on power Doppler examination.45 In addition, the presence of synovitis on power Doppler studies can be helpful in predicting which patients with undifferentiated inflammatory arthritis may progress to RA. The EULAR imaging recommendations45 also suggest that ultrasound may be helpful in demonstrating inflammation and/or early joint damage in patients with normal X-rays at initial diagnosis. However, the recommendations do not support the use of ultrasound as a substitute for plain films at this time. Together, EULAR-OMERACT have recently published the results of a joint ultrasound task force regarding the development of a “consensus-based scoring system” for the use of ultrasound in RA. However, the system has not yet been validated, and additional clinical studies are needed to see how this system will assist providers in caring for patients with RA.82

United Rheumatology supports the use of ultrasound as an adjunctive test for the diagnosis of RA when the diagnosis is confusing. The reader is referred to the United Rheumatology Guideline for Musculoskeletal Ultrasound for a discussion of the role of ultrasound in monitoring patients.

Rheumatoid arthritis is a chronic inflammatory disease. With proper management, patients can achieve periods of complete or near-complete remission, and stabilization of symptoms and function. However, episodes of flare do occur despite previously good control. Flares or acute worsening of inflammation are manifested by increased joint pain and systemic complaints such as fatigue and difficulty with activities of
daily living. When flares occur, changes in medication are often indicated, and these patients should be seen and re-evaluated quickly.

If a patient achieves a stable, durable remission, the current drug(s) should not be abruptly discontinued; instead, slow tapering (one drug at a time) may be considered, but only after a discussion with the patient that should address the risk of flares and the possibility of disease progression.

Follow-up evaluation of patients with RA should include at least the following:

- PtGA
- Patient Pain Assessment
- Physician Global Assessment
- MDHAQ or RAPID3
- Laboratory data, as appropriate
- CDAI
- Information about any change in medical history since the prior visit, including but not limited to hospitalizations or surgery
- Change in current medication list

The patient global, pain, and health assessments are covered with Questions 1, 2, and 4 of the MDHAQ (see Glossary).

Serious adverse events can occur with the use of boDMARDs and bsDMARDs. Therefore, it is important to monitor patients taking these medications carefully. All patients on boDMARDs, bsDMARDs, or tsDMARDs should have an annual TB evaluation and a flu vaccination. If patients on these drugs have an exposure to TB, then a screening should be performed, regardless of most recent test. An annual skin examination is also recommended.

**Depression**

Patients with RA have a higher incidence of depression than the general population.\(^{83}\)

The prevalence of depression in RA patients reported in the literature is inconsistent, but it is more common in women with RA than in men. One study reported depression to occur in 36.5% of women and 23.7% of men within 5 years of an RA diagnosis.\(^{84}\) Others reported depression in 16.8% of RA patients.\(^{85}\)

Another recent study followed 469 patients (73% women) with early RA over 8 years.\(^{86}\) The mean CDAI score of the entire group was consistent with high disease activity at the time of enrollment. Twenty-six percent of the patients reported depression at baseline; these patients had more comorbidities than the group not reporting depression. As expected, more women than men reported depression. The authors postulated that quickly controlling disease activity to the lowest possible level may limit depression in RA patients.
**Patient Reported Outcomes (PRO)**

United Rheumatology suggests the use of two patient reported outcomes (PRO) questionnaires at baseline and at each follow-up visit—the MDHAQ or RAPID3, and the PtGA. These patient questionnaires are only three of many PRO tools available. In a busy office, it is important to use patient questionnaires that are simple to understand, straightforward to answer, and not too time consuming. Both the MDHAQ and the RAPID3 include the PtGA and can be answered quickly by most patients.

The PtGA is answered using a visual acuity scale (VAS) placed on a 10-cm line. Each centimeter corresponds to a number from 1 to 10 and can be used for the calculation of CDAI.

A sample of the single question asked in the PtGA taken from a 2017 article is: “Considering all of the ways your disease affects you, how well are you doing in the past week?” (Page 203). The wording of the question for the PtGA is not standardized resulting in some differences in patient interpretation and response. However, a score of ≤ 2 (on a scale ranging from 1 to 10) is considered to be consistent with a global assessment of low disease activity.

Neither the MDHAQ nor the RAPID3 is used to calculate the CDAI disease activity scale recommended in this guideline. However, it is possible to use the MDHAQ or RAPID3 to obtain the PtGA required to calculate the CDAI score. These PRO tools can be completed by the patient in the waiting room or online prior to the visit. Occasionally, it may be necessary to have the questions asked by staff in the office or over the phone. These forms evaluate:

- Multiple activities of daily living, including advanced activities
- Sleep
- Mental and emotional health
- Pain
- Limits on physical activity
- Ability to walk 2 miles
- Physical function
- PtGA

The use of PRO questionnaires is important because it provides the physician with a more complete evaluation of the patient’s perception of his/her disease. The patient’s perspective on overall well-being is at times discordant with that of the provider, especially if the patient has not achieved the target of remission or LDA. According to Grossec, a patient’s perspective of overall well-being relates more to his/her perception of the burden of disease (which includes subjective aspects such as social support, function, mood, sleep, ability to perform activities of daily living, and disability) than to an improved disease activity score based on physical findings and laboratory data. Physicians, on the other hand, tend to evaluate how a patient is doing based on treatment targets such as disease activity scores that include clinical information such as swollen and/or tender joints, erosions, joint deformities, acute-phase reactants, PtGA, and a Physician Global Assessment.
The patient’s response to the questions in either the MDHAQ or RAPID3 and the physician’s response to the Physician Global Assessment and disease activity score should be considered to be complementary. If patient and physician responses are discordant, it is important to discuss the differences with the patient and suggest additional treatment such as physical therapy or anti-depressants to improve the patient’s perception of the burden of his/her disease.

**Glossary**

<table>
<thead>
<tr>
<th><strong>Biologics</strong></th>
<th>Include TNF inhibitors or non-TNF inhibitors (excluding anakinra).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>csDMARD monotherapy</strong></td>
<td>The use of a single csDMARD, usually MTX; however, any csDMARD such as leflunomide, sulfasalazine, or hydroxychloroquine can be used as monotherapy.</td>
</tr>
</tbody>
</table>
| **Disease-modifying antirheumatic drugs (DMARDs)** | A number of different types of DMARDs have become available in recent years. To enable precise reference to these medications, Smolen et al.\(^{91}\) have proposed the following nomenclature:  
  • **Conventional synthetic DMARDs (csDMARDs)** include MTX, leflunomide, sulfasalazine, hydroxychloroquine, and azathioprine.  
  • **Biologic DMARDs (boDMARDs)** include TNF biologics such as adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab; non-TNF biologics such as abatacept and rituximab; and IL-6 inhibitors such as tocilizumab and sarilumab.  
  • **Biosimilar DMARDs (bsDMARDs)** include the biosimilars Erelzi, Amjevita, Inflectra, and Renflexis.  
  • **Targeted synthetic DMARD (tsDMARD)** include the Janus kinase (JAK) inhibitors tofacitinib and baricitinib. |
| **Interleukin-6 (IL-6) inhibitors** | Tocilizumab and sarilumab. |
| **Multidimensional Health Assessment Questionnaire (MDHAQ)** | The MDHAQ is a practical patient self-report tool assessing that patients can complete in the waiting room. |
| **Non-TNF inhibitors** | Abatacept and rituximab. |
| **TNF inhibitors** | Adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab. |
| **Vectra DA** | Measure of 12 biomarkers for RA that provides a score indicating disease activity. |
## Appendix

### CDAI Calculator

<table>
<thead>
<tr>
<th>Clinical Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tender Joint Count (0-28)</td>
<td>0</td>
</tr>
<tr>
<td>Swollen Joint Count (0-28)</td>
<td>0</td>
</tr>
<tr>
<td>Patient Global Activity (0-10.0 cm)</td>
<td>0</td>
</tr>
<tr>
<td>Provider Global Activity (0-10.0 cm)</td>
<td>0</td>
</tr>
</tbody>
</table>

### Disease Activity

<table>
<thead>
<tr>
<th>Tool</th>
<th>Result</th>
<th>Range</th>
<th>Remission</th>
<th>Low</th>
<th>Moderate</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDAI</td>
<td>0.0</td>
<td>0-76</td>
<td>≤2.8</td>
<td>&gt;2.8 - 10.0</td>
<td>&gt;10.0 - 22.0</td>
<td>&gt;22.0</td>
</tr>
</tbody>
</table>
References


18. Maksymowych WP, Naides SJ, Bykerk V, Siminovitch KA, van Schaardenburg D, et al. Serum 14-3-3eta is a novel marker that complements current serological measurements to enhance detection of


90. Grossec L. Patient-reported outcomes in rheumatoid arthritis: why are they important and how should they be assessed. *Turk J Rheumatol* 2010;25:99-104.

# Document Updates

<table>
<thead>
<tr>
<th>Document Version</th>
<th>Description of Changes</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1.2016</td>
<td>Creation of first version</td>
<td>12 Sep 2016</td>
</tr>
<tr>
<td>1.1.2017</td>
<td>Updated with current research findings</td>
<td>26 Jun 2017</td>
</tr>
<tr>
<td>1.1.2018</td>
<td>2018 update</td>
<td></td>
</tr>
</tbody>
</table>